The passage of the Inflation Reduction Act of 2022 introduced a turning point for the biopharma industry. For the first time in the U.S., the federal government, through the Centers for Medicare & Medicaid Services (CMS), gained the power to negotiate maximum fair prices on select single-source drugs that are covered under Medicare Part D and, later, Part B. Under the law, the first ten drugs will have enforceable negotiated prices beginning January 1 2026. This regulatory shift means that companies accustomed to price autonomy must now rethink how they articulate value to payers and government programs.

Where Pricing Pressure Lands

The drugs selected for negotiation are those with the highest spending in Medicare and lacking generic or biosimilar competition. Since the list begins with ten Part D drugs for 2026 and expands thereafter (15 drugs in 2027 for Part D, then 15 for Part B/D in 2028, and 20 drugs per year from 2029 onward) the pressure is not isolated—it is cumulative. When a manufacturer anticipates that one of its drugs may be selected, revenue forecasting changes: the possibility of a mandated ceiling price forces earlier decisions on commercialization, patent extension, and lifecycle management.

How Biopharma Can Respond Strategically

Response requires a three-fold shift: rethink commercial models, strengthen real-world evidence capabilities, and adjust production and supply strategies. Commercial teams must develop pricing scenarios that align with possible maximum fair price ceilings rather than only with payer negotiations. Real-world evidence becomes mission-critical. Manufacturers will need to demonstrate outcomes and cost-effectiveness to make a case for value above a baseline. On the manufacturing side, companies must anticipate tighter margins: smarter outsourcing, automated batch manufacturing and modular facilities improve flexibility. These actions align with broader biopharma market trends where agility and data integration create competitive advantage.

Partnerships Are the New Normal

With pricing ceilings looming, business development strategies are migrating toward risk sharing, co-funded innovation and outcome-linked contracts. In the current environment, investors and CEOs evaluate biopharma firms not only on pipeline potential but also on policy resilience: the ability to launch, scale and commercialize under a regime with limit-priced treatments. Thus ecosystem partnerships—with contract manufacturing organizations, analytics firms and payers—are gaining relevance.

Also read: The Future of Biopharma: Can AI Algorithms Show Empathy in Drug Development?

Turning Reform into Advantage

Policy shifts present challenge but also a crucible for innovation. Rather than viewing negotiation mandates as a threat, forward-looking companies consider them design constraints. Those that embed the new pricing realities into their R&D strategy, evidence generation, supply chain architecture and commercial plans will emerge more resilient. In effect, the firms that thrive in 2025-2030 will not merely survive policy change, they will build value by adapting to it.